Beijing Novogene Technology Co. Ltd. agreed to acquire 10 Sequel Systems, so-Seq annotation from Pacific Biosciences of California, Inc. (NasdaqGS:PACB) on January 16, 2017.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
13.28 CNY | +0.30% | +2.31% | -43.10% |
Apr. 12 | Novogene Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Feb. 27 | Novogene Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-43.10% | 757M | |
-17.89% | 8.36B | |
+40.49% | 3.6B | |
-32.64% | 2.73B | |
-7.88% | 2.47B | |
-7.36% | 2.32B | |
-14.40% | 1.77B | |
-18.74% | 1.55B | |
-40.19% | 1.22B | |
+5.57% | 1.09B |
- Stock Market
- Equities
- 688315 Stock
- News Novogene Co., Ltd.
- Beijing Novogene Technology Co. Ltd. agreed to acquire 10 Sequel™ Systems, so-Seq™ annotation from Pacific Biosciences of California, Inc..